CurrentEndo coverage · page 4 of 5

The Lancet Diabetes & Endocrinology

Briefs 121–160 of 186 CurrentEndo has covered from this journal, newest publication first

Latest from The Lancet Diabetes & Endocrinology

All coverage, newest first

Lancet Diabetes Endocrinol17 May 2024
Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis
Meta-analysisT2D & other
Lancet Diabetes Endocrinol6 May 2024
Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review
Meta-analysisObesity
Lancet Diabetes Endocrinol3 May 2024
Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies
Cohort studyT2D & other
Lancet Diabetes EndocrinolMay 2024
Food additive emulsifiers and the risk of type 2 diabetes: analysis of data from the NutriNet-Santé prospective cohort study
Cohort studyT2D & other
Lancet Diabetes Endocrinol30 Apr 2024
Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial
Research articleObesity
Lancet Diabetes Endocrinol30 Apr 2024
Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial
Randomized controlled trialDiabetes in pregnancy
Lancet Diabetes Endocrinol5 Apr 2024
Associations of the glycaemic index and the glycaemic load with risk of type 2 diabetes in 127 594 people from 20 countries (PURE): a prospective cohort study
Cohort studyT2D & other
Lancet Diabetes Endocrinol29 Mar 2024
Familial aggregation and heritability of childhood-onset and adult-onset type 1 diabetes: a Swedish register-based cohort study
Cohort studyT1D
Lancet Diabetes Endocrinol27 Mar 2024
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
Meta-analysisT2D & other
Lancet Diabetes Endocrinol4 Mar 2024
Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years
Cohort studyBone & mineral
Lancet Diabetes Endocrinol1 Mar 2024
Classes and predictors of reversal in male patients with congenital hypogonadotropic hypogonadism: a cross-sectional study of six international referral centres
Cross-sectional studyReproductive endocrine
Lancet Diabetes Endocrinol26 Feb 2024
5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study
Randomized controlled trialT2D & other
Lancet Diabetes Endocrinol5 Feb 2024
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
Randomized controlled trialObesity
Lancet Diabetes Endocrinol5 Feb 2024
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Randomized controlled trialObesity
Lancet Diabetes Endocrinol1 Feb 2024
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial
Randomized controlled trialLipids & liver
Lancet Diabetes EndocrinolFebruary 2024
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants
Meta-analysisT2D & other
Lancet Diabetes EndocrinolFebruary 2024
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review
Meta-analysisComplications
Lancet Diabetes Endocrinol29 Jan 2024
A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis
Guideline or statementPituitary
Lancet Diabetes EndocrinolJanuary 2024
Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations
Guideline or statementT2D & other
Lancet Diabetes Endocrinol21 Dec 2023
Analysis of type 2 diabetes heterogeneity with a tree-like representation: insights from the prospective German Diabetes Study and the LURIC cohort
Cohort studyT2D & other
Lancet Diabetes Endocrinol21 Dec 2023
Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial
Secondary analysisT2D & other
Lancet Diabetes Endocrinol4 Dec 2023
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Secondary analysisT2D & other
Lancet Diabetes Endocrinol4 Dec 2023
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial
Secondary analysisT2D & other
Lancet Diabetes Endocrinol4 Dec 2023
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Secondary analysisComplications
Lancet Diabetes Endocrinol1 Dec 2023
Vitamin D supplements for fracture prevention in schoolchildren in Mongolia: analysis of secondary outcomes from a multicentre, double-blind, randomised, placebo-controlled trial
Secondary analysisBone & mineral
Lancet Diabetes Endocrinol1 Dec 2023
Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses
Cohort studyBone & mineral
Lancet Diabetes Endocrinol3 Nov 2023
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
Meta-analysisT1D
Lancet Diabetes Endocrinol18 Oct 2023
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Randomized controlled trial
Lancet Diabetes Endocrinol4 Oct 2023
Faster-acting insulin aspart versus insulin aspart in the treatment of type 1 or type 2 diabetes during pregnancy and post-delivery (CopenFast): an open-label, single-centre, randomised controlled trial
Randomized controlled trialDiabetes in pregnancy
Lancet Diabetes Endocrinol25 Sep 2023
Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS)
Secondary analysisT2D & other
Lancet Diabetes Endocrinol11 Sep 2023
Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation
Cohort studyT2D & other
Lancet Diabetes Endocrinol8 Sep 2023
The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis
Meta-analysisThyroid
Lancet Diabetes Endocrinol21 Aug 2023
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study
Randomized controlled trialEndocrine cancer
Lancet Diabetes Endocrinol4 Aug 2023
National UK guidelines for the management of paediatric craniopharyngioma
Guideline or statementPituitary
Lancet Diabetes Endocrinol24 Jul 2023
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
Cohort studyT2D & other
Lancet Diabetes Endocrinol21 Jul 2023
Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study
Cohort studyLipids & liver
Lancet Diabetes Endocrinol17 Jul 2023
Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study
Cohort studyThyroid
Lancet Diabetes Endocrinol7 Jul 2023
Diagnostic challenges in cyclic Cushing's syndrome: a systematic review
Meta-analysisAdrenal
Lancet Diabetes Endocrinol3 Jul 2023
Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial
Randomized controlled trialT2D & other
Lancet Diabetes Endocrinol27 Jun 2023
Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins
Meta-analysisT1D

All 186 Briefs in ExploreShowing Briefs 121–160 of 186, newest first